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It has come to our attention that during production of 
the original article, some of the column headings were 
missing from Tables 1 and 2. The corrected Tables 1 and 
2 can be found below. The publisher apologises for any 
inconvenience caused.
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Table 1 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents prior to generic availability
Medication Monthly cost after deductible Monthly cost in gap Monthly cost in catastrophic
Median of state mean costs Median of state mean costs Median of state mean costs
$, (Range of mean costs) $, (Range of mean costs) $, (Range of mean costs)
2007 2010 Change 
(%)
2007 2010 Change 
(%)
2007 2010 Change 
(%)
Arimidex 39.64 (38.37–48.19) 62.83 (60.00–74.75) +58 258.64 (247.44–263.47) 392.84 (375.66–418.58) +52 13.18 (12.68–13.32) 19.65 (19.03–20.93) +49
Aromasin 42.57 (40.72–50.94) 86.50 (81.51–101.08) +103 267.56 (255.21–273.62) 353.98 (351.86–377.07) +32 13.66 (13.07–13.79) 17.70 (17.59–18.85) +30
Femara 41.92 (39.38–51.11) 89.03 (80.95–102.77) +112 277.65 (249.14–282.54) 433.42 (430.46–461.42) +56 14.16 (12.96–14.34) 21.67 (21.55–23.07) +53
Tamoxifen 6.19 (5.95–9.22) 5.98 (5.66–6.75) −3 21.32 (20.36–25.42) 15.52 (15.03–18.90) −27 2.26 (2.20–2.70) 2.60 (2.58–2.75) +15
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Table 2 Trajectory of costs under Medicare Part D for breast cancer adjuvant endocrine agents before and after availabil‑
ity of generic alternatives
a First year generic formulation was available to Medicare Part D beneficiaries; generic cost provided
Medication Monthly cost after deductible Monthly cost in gap Monthly cost in catastrophic
Median of state mean costs Median of state mean costs Median of state mean costs
$, (Range of mean costs) $, (Range of mean costs) $, (Range of mean costs)
2007 2011a Change 
(%)
2007 2011a Change 
(%)









42.57 (40.72–50.94) 49.50 (42.34–118.68) +16 267.56 (255.21–273.62) 244.51 (228.61–270.95) −9 13.66 (13.07–13.79) 14.41 (13.51–71.41) +6
Femara/
Letrozole
41.92 (39.38–51.11) 69.31 (59.69–85.17) +65 277.65 (249.14–282.54) 225.13 (209.10–252.23) −19 14.16 (12.96–14.34) 38.53 (33.70–57.15) +172
Tamoxifen 6.19 (5.95–9.22) 5.54 (5.12–6.89) −11 21.32 (20.36–25.42) 13.17 (12.44–21.11) −38 2.26 (2.20–2.70) 2.73 (2.50–3.47) +21
The online version of the original article can be found under 
doi:10.1186/s40064‑015‑0827‑8.
